This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chi, S.-G. Articles by Park, J.-H. Search for Related Content PubMed PubMed Citation Articles by Chi, S.-G. Articles by Park, J.-H.

Elevated and Biallelic Expression of p73 Is Associated with Progression of Human Bladder Cancer

Department of Pathology and Kohwang Medical Research Institute [S-G. Chi, J-H. P.], and Department of Urology [S-G. Cha., S-J. L., C-H. L., J. I. K.], School of Medicine, Kyung Hee University, 130-701 Seoul, Republic of Korea

p73, a member of the p53 family at 1p36.3, has been demonstrated to be expressed monoallelically and induce apoptosis or G₁ arrest of the cell cycle. To explore the candidacy of p73 as a suppressor in bladder tumorigenesis, we examined expression level, allelic origin, and mutation of p73 mRNA in 45 primary bladder carcinomas. Quantitative PCR analysis showed no allelic loss of the gene but showed various levels of mRNA expression in both carcinoma and noncancerous tissues. Elevated expression of p73 was frequently observed in carcinoma tissues [18 (40.0%) of 45] and showed a strong correlation with tumor stage or grade. Allotyping analysis using a StyI polymorphism detected biallelic expression in 12 (52.2%) of 23 heterozygous carcinomas but none in 4 noncancerous tissues. Tumor-specific biallelic expression was also identified from one matched set. In addition, 8 (66.7%) of these 12 expressed high levels of p73 mRNA, whereas only 2 (18.2%) of 11 monoallelic expressors showed high expression, which suggests that the increased expression of p73 might be caused by the transcriptional activation of a silent allele in carcinomas. Single-strand conformational polymorphism analysis of the entire coding region of p73 revealed no mutation, whereas 12 (26.7%) of the same set showed p53 alterations. No relationship between expression of p73 and p53 mutation or expression of p21^Waf1 or MDM2 was identified. Taken together, our data argue that p73 does not play a role as a tumor suppressor in bladder carcinogenesis and suggest that the activation of a silent allele may contribute to the progression of bladder tumors.

This article has been cited by other articles:

				E. H. Jensen, J. M. Lewis, J. M. McLoughlin, M. D. Alvarado, A. Daud, J. Messina, S. Enkemann, T. J. Yeatman, V. K. Sondak, and A. I. Riker Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma Ann. Surg. Oncol., April 1, 2007; 14(4): 1416 - 1423. [Abstract] [Full Text] [PDF]

				H. Li, L. Yao, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Dong, B. Lin, J. Li, et al. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival Carcinogenesis, February 1, 2007; 28(2): 372 - 377. [Abstract] [Full Text] [PDF]

				G. Dominguez, J. M. Garcia, C. Pena, J. Silva, V. Garcia, L. Martinez, C. Maximiano, M. E. Gomez, J. A. Rivera, C. Garcia-Andrade, et al. {Delta}TAp73 Upregulation Correlates With Poor Prognosis in Human Tumors: Putative In Vivo Network Involving p73 Isoforms, p53, and E2F-1 J. Clin. Oncol., February 10, 2006; 24(5): 805 - 815. [Abstract] [Full Text] [PDF]

				M. Guan, H.-X. Peng, B. Yu, and Y. Lu p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma Jpn. J. Clin. Oncol., May 1, 2003; 33(5): 215 - 220. [Abstract] [Full Text] [PDF]

				W. J. Freebern, J. L. Smith, S. S. Chaudhry, C. M. Haggerty, and K. Gardner Novel Cell-specific and Dominant Negative Anti-apoptotic Roles of p73 in Transformed Leukemia Cells J. Biol. Chem., January 17, 2003; 278(4): 2249 - 2255. [Abstract] [Full Text] [PDF]

				X.-F. Sun p73 Overexpression Is a Prognostic Factor in Patients with Colorectal Adenocarcinoma Clin. Cancer Res., January 1, 2002; 8(1): 165 - 170. [Abstract] [Full Text] [PDF]

				M.-L. Lu, F. Wikman, T. F. Orntoft, E. Charytonowicz, F. Rabbani, Z. Zhang, G. Dalbagni, K. S. Pohar, G. Yu, and C. Cordon-Cardo Impact of Alterations Affecting the p53 Pathway in Bladder Cancer on Clinical Outcome, Assessed by Conventional and Array-based Methods Clin. Cancer Res., January 1, 2002; 8(1): 171 - 179. [Abstract] [Full Text] [PDF]

				M.-G. Lee, H.-Y. Kim, D.-S. Byun, S.-J. Lee, C.-H. Lee, J. I. Kim, S.-G. Chang, and S.-G. Chi Frequent Epigenetic Inactivation of RASSF1A in Human Bladder Carcinoma Cancer Res., September 1, 2001; 61(18): 6688 - 6692. [Abstract] [Full Text] [PDF]

				M. S. Irwin and W. G. Kaelin p53 Family Update: p73 and p63 Develop Their Own Identities Cell Growth Differ., July 1, 2001; 12(7): 337 - 349. [Full Text] [PDF]

				A. K. El-Naggar, S. Lai, G. L. Clayman, B. Mims, S. M. Lippman, M. Coombes, M. A. Luna, and G. Lozano p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas Carcinogenesis, May 1, 2001; 22(5): 729 - 735. [Abstract] [Full Text] [PDF]

				F. Vikhanskaya, S. Marchini, M. Marabese, E. Galliera, and M. Broggini p73{{alpha}} Overexpression Is Associated with Resistance to Treatment with DNA-damaging Agents in a Human Ovarian Cancer Cell Line Cancer Res., February 1, 2001; 61(3): 935 - 938. [Abstract] [Full Text]

				B.-J. Park, S.-J. Lee, J. I. Kim, S.-J. Lee, C.-H. Lee, S.-G. Chang, J.-H. Park, and S.-G. Chi Frequent Alteration of p63 Expression in Human Primary Bladder Carcinomas Cancer Res., July 1, 2000; 60(13): 3370 - 3374. [Abstract] [Full Text]

				M.-J. Kang, B.-J. Park, D.-S. Byun, J.-I. Park, H.-J. Kim, J.-H. Park, and S.-G. Chi Loss of Imprinting and Elevated Expression of Wild-Type p73 in Human Gastric Adenocarcinoma Clin. Cancer Res., May 1, 2000; 6(5): 1767 - 1771. [Abstract] [Full Text]

				F. Vikhanskaya, M. D'Incalci, and M. Broggini p73 competes with p53 and attenuates its response in a human ovarian cancer cell line Nucleic Acids Res., January 15, 2000; 28(2): 513 - 519. [Abstract] [Full Text] [PDF]